Human Clinical Trials
In a Russian clinical trial Carnosine eye-drops were used to treat 96 patients aged 60 and above. All the patients had senile cataract in various degrees of maturity. The duration of the disease in these patients ranged between 2 and 21 years. The patients instilled 1 or 2 drops into each eye 3 or 4 times a day, for a period of 3 to 6 months. The results showed that there was a pronounced effect on senile cataract, the rate was 100% (i. e. all patients experienced an improvement). For the more mature senile cataract the effective rate was still an extremely impressive 80%. Importantly, it was also noted that there were no side effects in any of the cases.
A second clinical study was designed to document and quantify the changes in lens clarity over a 6 to 24 month period. The averageage of the participants was 65 and all suffered from senile cataract of a minimal to an advanced opacification. The patients received either a 1% solution of N-acetylcarnosine eye-drops or a placebo as 2-drops twice a day into each eye. The results at 6 months were impressive; 88.9% of all eyes treated with N-acetylcarnosine had an improvement of glare sensitivity. Furthermore, 90% of the eyes treated with N-acetylcarnosine showed an improvement in visual acuity. In contrast, there was little change in the eye quality of the placebo group at 6 months and the placebo group also experienced a gradual deterioration at 12 to 24 months.
Another study evaluated patients who had various degrees of eyesight impairment but who did not have the symptoms of cataract. After a course of treatment ranging from 2 to 6 months the conclusion was that the eye-drops alleviated eye tiredness and continued to improve eyesight (i. e. there was more clear vision). This is an indicator that the eye-drops have a value both for preventative purposes as well as medical applications. Clinical Publications